Novel Insights From a Phase II MEK Inhibitor Trial in BRAF Mutant Melanoma

from Journal of Clinical Oncology (JCO) Podcast

A discussion of a phase 2 trial of a MEK inhibitor in patients with V600 BRAF mutations and consideration of other relevant results with targeted therapies in this population.

Episode metadata supplied by the publisher feed · Published Dec 19, 2012

Embed this episode

Attribution link and audio player

NOW PLAYING

Novel Insights From a Phase II MEK Inhibitor Trial in BRAF Mutant Melanoma

0:00 7:27

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Journal of Clinical Oncology (JCO) Podcast?

This episode is 7 minutes long.

When was this Journal of Clinical Oncology (JCO) Podcast episode published?

This episode was published on December 19, 2012.

Can I download this Journal of Clinical Oncology (JCO) Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!